Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Glycopyrronium Bromide (CHF5259) DPI in COPD
NCT02680197Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of glycopyrronium bromide in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Feb 2016; status: completed.
02
Drugs
glycopyrronium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02680197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680197.